Bartter Syndrome

An enlarged renin-making cell cluster beside a glomerulus
An enlarged renin-making cell cluster beside a glomerulus
Calcium deposits in the kidney, seen in antenatal Bartter
Calcium deposits in the kidney, seen in antenatal Bartter
Potassium-rich foods; low blood potassium is a hallmark
Potassium-rich foods; low blood potassium is a hallmark

Bartter syndrome is a group of inherited renal tubular disorders caused by mutations, mostly autosomal recessive with X-linked and autosomal dominant forms, that disrupt ion transport in the thick ascending limb (TAL) of the loop of Henle, leading to salt wasting, hypokalemia, metabolic alkalosis, and hyperreninemia with low to normal blood pressure.

🔃 Interactive Visualization The Sodium–Potassium Pump — why you have a voltage Run the pump that gives every cell its charge — three sodium out, two potassium in, on Mg-ATP — then drop the magnesium and see exactly why low potassium refuses to correct. Launch →

Table of Contents

  1. Overview and Pathophysiology
  2. Genetic Types (I through V)
  3. Antenatal Bartter Syndrome
  4. Classic Bartter Syndrome (Type III)
  5. Laboratory Findings and Diagnosis
  6. Differential Diagnosis
  7. Treatment and Management
  8. Prognosis and Long-Term Outcomes
  9. Key Research Papers
  10. Connections
  11. Featured Videos

Overview and Pathophysiology

Bartter syndrome is a group of mostly autosomal recessive renal tubular disorders, with X-linked and autosomal dominant forms, caused by defective ion transport in the thick ascending limb (TAL) of the loop of Henle. The TAL normally reabsorbs approximately 25% of filtered NaCl via the Na-K-2Cl cotransporter (NKCC2). Defects in NKCC2 or its associated channels lead to a cascade of downstream consequences: salt wasting causes volume depletion, which activates the renin-angiotensin-aldosterone system (RAAS), producing secondary hyperaldosteronism. The resulting aldosterone excess drives potassium excretion in the collecting duct, producing hypokalemia and metabolic alkalosis.

The phenotype closely mimics chronic furosemide use, because furosemide exerts its diuretic effect by blocking NKCC2 — the same transporter defective in Bartter syndrome. Critically, increased NaCl delivery to the macula densa stimulates prostaglandin E2 (PGE2) overproduction, which amplifies renin release and contributes to the severe polyuria seen especially in antenatal forms. Despite markedly elevated renin and aldosterone, blood pressure remains normal or low because the primary defect prevents volume retention.

The 2021 European expert consensus describes Bartter syndrome as a rare inherited salt-losing disorder of the kidney tubules with secondary hyperaldosteronism, low blood potassium and low blood chloride with metabolic alkalosis (hypokalemic and hypochloremic metabolic alkalosis), and low to normal blood pressure.

Back to Table of Contents

Genetic Types (I through V)

Five numbered genetic types of Bartter syndrome are described, each caused by a mutation in a different component of the TAL transport machinery; a further X-linked form, found in 2016, is listed after them:

Back to Table of Contents

Antenatal Bartter Syndrome (Types I and II)

Antenatal Bartter syndrome (Types I and II) presents prenatally or in the neonatal period and represents the most severe end of the clinical spectrum. Massive fetal polyuria — caused by failure of NaCl reabsorption in the TAL — leads to polyhydramnios (excessive accumulation of amniotic fluid), frequently the first clinical clue detected on routine obstetric ultrasound. Premature birth is common, often occurring before 34 weeks gestation.

Postnatally, affected infants display life-threatening salt wasting with severe dehydration. Serum sodium may be initially elevated (hypernatremia from free water deficit) before transitioning to hyponatremia as the pattern evolves. Profound hypercalciuria is characteristic of Types I and II, leading to nephrocalcinosis — calcium deposits in the renal medulla visible on ultrasound — which can progress to chronic kidney disease if untreated. Failure to thrive and poor weight gain are universal. Elevated prostaglandin E2 levels contribute to episodic fever.

Antenatal diagnosis is possible through amniocentesis (elevated amniotic fluid chloride concentration) or fetal urine sampling, and genetic testing of chorionic villus or amniocyte DNA confirms the mutation. Early initiation of indomethacin after delivery — to suppress prostaglandin synthesis — is the cornerstone of treatment and dramatically improves outcomes.

Back to Table of Contents

Classic Bartter Syndrome (Type III)

Type III Bartter syndrome, caused by CLCNKB mutations, is the most common form and typically presents in early childhood, though milder cases may not be recognized until adulthood. The cardinal clinical features are:

Type III typically does not cause the severe nephrocalcinosis seen in antenatal forms, though some patients develop mild hypercalciuria. The phenotypic variability of Type III is explained by the range of CLCNKB mutations — some cause near-complete loss of ClC-Kb function (severe, antenatal-like), while others preserve partial function (mild, Gitelman-like). This overlap complicates clinical classification and underscores the importance of genetic testing.

A study of 115 patients with CLCNKB mutations sorted them into three clinical pictures: 29.5% antenatal or neonatal (polyhydramnios or diagnosis in the first month of life), 44.5% classic disease diagnosed in childhood, and 26.0% a Gitelman-like picture found by chance in childhood or adulthood. Severe mutations, and missense mutations leaving little channel function, went with a younger age at diagnosis.

Back to Table of Contents

Laboratory Findings and Diagnosis

The biochemical signature of Bartter syndrome is distinctive:

Urine studies are critical for differential diagnosis:

In a single-center study of 45 children with Bartter or Gitelman syndrome, those with CLCNKB mutations had the lowest serum potassium and magnesium and the highest serum bicarbonate. Fractional excretion of chloride (a measure of how much filtered chloride the kidney lets go into the urine) was above 0.5% in every patient before supplements, and the authors describe it as a useful screening test for kidney salt loss in children with hypokalemic alkalosis.

Renal ultrasound is used to check for nephrocalcinosis, particularly in antenatal-onset cases. Definitive diagnosis is established by next-generation sequencing (NGS) panel targeting SLC12A1, KCNJ1, CLCNKB, BSND, CLCNKA, and CASR.

Back to Table of Contents

Differential Diagnosis

Several conditions share features with Bartter syndrome; these are the features that separate them:

Back to Table of Contents

Treatment and Management

Treatment is lifelong and requires a multi-drug regimen targeting both electrolyte replacement and the upstream prostaglandin-driven renin excess:

Monitoring described for this condition includes regular electrolyte panels (every 3–6 months when stable), renal function tests, blood pressure, growth parameters in children, and annual renal ultrasound (nephrocalcinosis surveillance), with audiologic evaluation at diagnosis and periodically for Type IV patients.

What is not known: the 2021 European expert consensus states that, as with many rare diseases, there is a paucity of clinical studies that could guide diagnosis and treatment. The authors of the Korean study describe a large potassium need, along with potassium-sparing drugs, throughout life, while noting that patients tend to improve with age.

Back to Table of Contents

Prognosis and Long-Term Outcomes

With consistent treatment, many patients with Bartter syndrome reach near-normal growth and quality of life, but long-term studies give a mixed picture. A single-center study of 45 children with Bartter or Gitelman syndrome reported a satisfactory prognosis during childhood, with growth impaired but within the normal range (median height standard deviation score -1.2). In 54 Korean patients, at a median 8 years of follow-up, 41% had short stature (height below the 3rd percentile) and 11% had chronic kidney disease stage G3 to G5. Cognitive development is unaffected. Life expectancy approaches normal with good adherence to therapy. Several long-term risks are followed over time:

Genetic counseling is available to families. In the autosomal recessive forms, both parents of an affected child are obligate carriers of the mutation and each sibling has a 25% risk of being affected.

Back to Table of Contents

Key Research Papers

  1. Simon DB, Karet FE, Hamdan JM, et al. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet. 1996;13(2):183-188. — PubMed PMID: 8640224
  2. Simon DB, Karet FE, Rodriguez-Soriano J, et al. Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet. 1996;14(2):152-156. — PubMed PMID: 8841184
  3. Simon DB, Bindra RS, Mansfield TA, et al. Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet. 1997;17(2):171-178. — PubMed PMID: 9326936
  4. Birkenhäger R, Otto E, Schürmann MJ, et al. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet. 2001;29(3):310-314. — PubMed PMID: 11687798
  5. Hebert SC. Bartter syndrome. Curr Opin Nephrol Hypertens. 2003;12(5):527-532. — PubMed PMID: 12920401
  6. Fremont OT, Chan JC. Understanding Bartter syndrome and Gitelman syndrome. World J Pediatr. 2012;8(1):25-30. — PubMed PMID: 22282380
  7. Kleta R, Bockenhauer D. Bartter syndromes and other salt-losing tubulopathies. Nephron Physiol. 2006;104(2):p73-p80. — PubMed PMID: 16785747
  8. Seys E, Andrini O, Keck M, et al. Clinical and Genetic Spectrum of Bartter Syndrome Type 3. J Am Soc Nephrol. 2017;28(8):2540-2552. — PubMed PMID: 28381550
  9. Walsh PR, Tse Y, Ashton E, et al. Clinical and diagnostic features of Bartter and Gitelman syndromes. Clin Kidney J. 2018;11(3):302-309. — PubMed PMID: 29942493
  10. Proesmans W. Threading through the mizmaze of Bartter syndrome. Pediatr Nephrol. 2006;21(7):896-902. — PubMed PMID: 16773399
  11. Konrad M, Nijenhuis T, Ariceta G, et al. Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders. Kidney Int. 2021;99(2):324-335. — PubMed PMID: 33509356
  12. Laghmani K, Beck BB, Yang SS, et al. Polyhydramnios, Transient Antenatal Bartter's Syndrome, and MAGED2 Mutations. N Engl J Med. 2016;374(19):1853-1863. — PubMed PMID: 27120771
  13. Choi N, Kim SH, Bae EH, et al. Long-term outcome of Bartter syndrome in 54 patients: A multicenter study in Korea. Front Med (Lausanne). 2023;10:1099840. — PubMed PMID: 36993809

Back to Table of Contents

Connections

Back to Table of Contents